已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Treatment of Degenerative Disc Disease With Allogeneic Mesenchymal Stem Cells: Long-term Follow-up Results

间充质干细胞 医学 干细胞 随机对照试验 纳入和排除标准 变性(医学) 退行性椎间盘病 骨髓 间质细胞 生活质量(医疗保健) 临床试验 疾病 移植 外科 病理 内科学 生物 腰椎 替代医学 护理部 遗传学
作者
David C. Noriega,Francisco Ardura,Rubén Hernández-Ramajo,Miguel Ángel Martín-Ferrero,I. Sánchez Lite,Borja Toribio,Mercedes Alberca,Verónica García,José M. Moraleda,Margarita González‐Vallinas,Ana Sánchez,Javier García‐Sancho
出处
期刊:Transplantation [Ovid Technologies (Wolters Kluwer)]
卷期号:105 (2): e25-e27 被引量:15
标识
DOI:10.1097/tp.0000000000003471
摘要

Degenerative disc disease frequently results in severe low back pain, which represents a public health problem with great economic and quality of life impact. Chronic cases often require surgery, which can lead to biomechanical problems and accelerated degeneration of the adjacent segments.1,2 Both autologous3 and allogeneic4 mesenchymal stromal cell (MSC) treatments have shown feasibility, safety, and strong indications of clinical efficacy 1 year after cell transplantation. Allogeneic cells are logistically more convenient for generalized treatment (see discussion in Noriega et al4), and the durability of the effect is essential. We present here the long-term (3.5 ± 0.1 y; mean ± SEM; n = 23) results of our randomized, controlled trial using allogeneic bone marrow-derived MSCs.4 We originally randomized 24 patients, 17 men and 7 women, with chronic back pain diagnosed with lumbar disk degeneration (to 1 or 2 discs) and unresponsive to conservative treatments into 2 groups. The mean (±SEM) age was 38 years (±2 y). The further details of the baseline demographics and the inclusion and exclusion criteria are given in Noriega et al.4 The bone marrow cells were obtained from healthy donors, purified, and expanded for 24–27 days (3 passages) under Good Manufacturing Practice criteria (details in Orozco et al3 and Noriega et al4). The treatment group received the allogeneic bone marrow MSCs as intradisc injections of 25 × 106 cells per segment under local anesthesia. The control group received sham infiltration in the paravertebral musculature with the anesthetic. Clinical outcomes were followed for 1 year, and included evaluation of pain (Visual Analog Scale: 0–100), and disability (Oswestry Disability Index).5 Disc quality was followed using MRI and quantified according to the Pfirrmann grading (1–5). Feasibility and safety were confirmed, and indications of clinical efficacy were identified. The MSC-treated patients showed rapid and significant improvements in the algofunctional indices versus the controls. Furthermore, disc degeneration quantified by the Pfirrmann grading improved in the MSC-treated patients and worsened in the controls.4 Here, we report the results of the patient follow-up at (mean ± SE; n = 23) 3.5 ± 0.1 years from the original interventions. No serious adverse effects were recorded during this extension period for either treatment or control group. Figure 1A–D summarizes the evolution of the clinical data. For the test group, the early pain improvements and the Oswestry Disability Index improvements during the first year persisted 3.5 years later (Figure 1A and B). The therapeutic efficiency of the MSC treatment was estimated from the pain relief and the disability improvement in the Huskisson plot and was 0.28 at 1 year after the intervention. By 3.5 years, the therapeutic efficiencies increased to 0.60 (pain relief) and 0.71 (disability) (Figure 1C and D). The control patients did not show any significant healing at 3.5 years after intervention (efficiency, 0.18 for pain, 0.0 for disability; Figure 1C and D, respectively). Of note, the MSC-treated patients showed 2 distribution patterns: one as a subpopulation of “responders” who lie close to the “perfect treatment” line and the other as a subpopulation of “non responders” with no significant difference from the control patients (Figure 1C and D).FIGURE 1.: Pain, disability, and Pfirrmann grading evolution for the control and mesenchymal stromal cell (MSC)-treated patients. A, Evolution over time of lower back pain measured by a Visual Analog Scale (VAS; expressed as 0%–100%). Data are means ± SD for the control group (inverted triangles) and the MSC-treated group (filled circles). B, Evolution over time of disability measured by the Oswestry Disability Index (ODI) (expressed as 0%–100%).5 Other details as in (A). C and D, Correlations between improved lower back pain (C, VAS) and disability (D, ODI) and the initial baseline values for each patient,6 measured at 42 mo from the intervention (3.5 ± 0.1 y; n = 23). The discontinuous blue line shows the slope of 1.0 that represents “perfect treatment” with complete relief of pain (C) and disability (D). The slopes of the lines are given at the right. Other details as in (A). E and F, MRI assessment of nucleus pulposus evolution according to the Pfirrmann grading. The Pfirrmann grading measures affectation (grades 1–5), taking into account the structure of the disc, the distinction of the nucleus pulposus and the annulus fibrous, the signal intensity, and the height of the disc. Data are means ± SE for baseline (0) and 6, 12, and 42 mo (ie, 3.5 y) after the intervention for the control group (E) and the MSC-treated group (F). *P < 0.05; **P < 0.01; ***P < 0.001 vs baseline (ANOVA, Bonferroni multiple comparisons). NS, not significant.For the structural changes of the affected discs, at the end of the first year of treatment, we reported significant improvements for the MSC treatment, as seen by the decreased Pfirrmann gradings defined from MRI.4 At 3.5 years, the decreased Pfirrmann grading was maintained in the MSC-treated patients (P < 0.01 versus baseline), whereas the control patients showed indication of continued increase in the Pfirrmann grading (P < 0.001 versus baseline). Thus, from baseline to 42 months, the Pfirrmann grading significantly increased in the controls by 1.0 (baseline, 3.15; 42 mo, 4.16; Figure 1E), whereas for the MSC-treated patients, there was a significant decrease of >0.6 (baseline, 3.59; 42 mo, 2.94; Figure 1F). This contrasts with the repeatedly reported rapid clearance of MSCs from living tissues.7 This persistent improvement of the phenotype achieved has been attributed to epigenetic actions of the MSCs.8,9 Overall, these long-term data reaffirm that MSCs appear to be a valid alternative for treatment of degenerative disc disease because they can provide effective and durable pain relief together with objective improvements to disc degeneration. This intervention is also simple, although the MSC production process is expensive. The major limitations are the difficulties to generalize the results to large populations, as well as the lack of detailed determination of the optimal dosage of cells. New studies are under way to confirm the durable results reported here in a large series of patients (eg, the pan-European RESPINE clinical trial), and to investigate upgrades to the MSC production protocol, to make the generalization of this MSC therapy possible. ACKNOWLEDGMENTS We thank Mr. Jesús Fernández from IBGM, Ms. Sandra Güemes from Citospin, and Ms. Carmen Barbero from ITRT for their technical support.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
2秒前
北国发布了新的文献求助10
3秒前
alan发布了新的文献求助10
4秒前
磨磨唧唧应助嘿嘿采纳,获得10
4秒前
汤万天完成签到,获得积分10
5秒前
7秒前
休眠火山发布了新的文献求助10
8秒前
libaibai完成签到 ,获得积分10
8秒前
英俊的铭应助聪慧的致远采纳,获得10
9秒前
10秒前
12秒前
CodeCraft应助xuqianlan采纳,获得10
12秒前
13秒前
yyy发布了新的文献求助10
14秒前
无花果应助兴奋的天蓝采纳,获得30
14秒前
Pig-prodigy发布了新的文献求助10
16秒前
Zyl发布了新的文献求助10
16秒前
17秒前
嘟嘟完成签到 ,获得积分10
17秒前
青苹果完成签到,获得积分10
22秒前
LY学生完成签到,获得积分10
27秒前
27秒前
honey完成签到,获得积分10
32秒前
11发布了新的文献求助10
33秒前
共享精神应助Zyl采纳,获得10
33秒前
共享精神应助ant采纳,获得10
33秒前
英俊的铭应助休眠火山采纳,获得10
35秒前
39秒前
39秒前
41秒前
zzmAZUSA完成签到,获得积分20
43秒前
何事秋风发布了新的文献求助10
45秒前
泥巴发布了新的文献求助10
45秒前
Lucas应助yayayang采纳,获得10
46秒前
49秒前
49秒前
英姑应助小九采纳,获得100
50秒前
憨憨发布了新的文献求助10
52秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Semiconductor Process Reliability in Practice 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 600
GROUP-THEORY AND POLARIZATION ALGEBRA 500
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3234297
求助须知:如何正确求助?哪些是违规求助? 2880629
关于积分的说明 8216470
捐赠科研通 2548256
什么是DOI,文献DOI怎么找? 1377635
科研通“疑难数据库(出版商)”最低求助积分说明 647925
邀请新用户注册赠送积分活动 623302